IMPACT SCORE JOURNAL RANKING CONFERENCE RANKING Conferences Journals Workshops Seminars SYMPOSIUMS MEETINGS BLOG LaTeX 5G Tutorial Free Tools

Search About Journals, Conferences, and Book Series

Uspehi Molekularnoj Onkologii

Impact, Factor and Metrics, Impact Score, Ranking, h-index, SJR, Rating, Publisher, ISSN, and More

Last Updated on October 31, 2023

Impact Score

2022-2023

0.17

h-Index

2022-2023

 2

Rank

2022-2023

 25726

SJR

2022-2023

 0.107

Note: The impact score or impact index shown here is equivalent to the average number of times documents published in a journal/conference in the past two years have been cited in the current year (i.e., Cites / Doc. (2 years)). It is based on Scopus data and can be a little higher or different compared to the impact factor (IF) produced by Journal Citation Report. Please refer to the Web of Science data source to check the exact journal impact factor ™ (Thomson Reuters) metric.

Important Metrics and Factor

Title Uspehi Molekularnoj Onkologii
Abbreviation Usp. Mol. Onkol.
Publication Type Journal
Subject Area, Categories, Scope Biochemistry (medical) (Q4); Cancer Research (Q4); Genetics (clinical) (Q4); Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q4)
h-index 2
Overall Rank/Ranking 25726
SCImago Journal Rank (SJR) 0.107
Impact Score 0.17
Publisher ABC-press Publishing House
Country Russian Federation
ISSN 2313805X, 24133787
Best Quartile Q4
Coverage History 2019-2022




About Uspehi Molekularnoj Onkologii


Uspehi Molekularnoj Onkologii is a journal covering the technologies/fields/categories related to Biochemistry (medical) (Q4); Cancer Research (Q4); Genetics (clinical) (Q4); Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q4). It is published by ABC-press Publishing House. The overall rank of Uspehi Molekularnoj Onkologii is 25726. According to SCImago Journal Rank (SJR), this journal is ranked 0.107. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 2. The best quartile for this journal is Q4.

The ISSN of Uspehi Molekularnoj Onkologii journal is 2313805X, 24133787. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Uspehi Molekularnoj Onkologii is cited by a total of 9 articles during the last 3 years (Preceding 2022).


Uspehi Molekularnoj Onkologii Impact IF 2022-2023


The Impact IF 2022 of Uspehi Molekularnoj Onkologii is 0.17, which is computed in 2023 as per its definition. Uspehi Molekularnoj Onkologii IF is decreased by a factor of 0.21 and approximate percentage change is -55.26% when compared to preceding year 2021, which shows a falling trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.

Table Setting

Uspehi Molekularnoj Onkologii Impact IF 2023 Prediction


Impact IF 2022 of Uspehi Molekularnoj Onkologii is 0.17. If the same downward trend persists, Impact IF may fall in 2023 as well.


Impact IF Trend


Year wise Impact IF of Uspehi Molekularnoj Onkologii. Based on Scopus data.


Year Impact IF
2023/2024 Coming Soon
2022 0.17
2021 0.38
2020 0.33
2019 0.00

Uspehi Molekularnoj Onkologii h-index


  Table Setting

Uspehi Molekularnoj Onkologii has an h-index of 2. It means 2 articles of this journal have more than 2 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.




Uspehi Molekularnoj Onkologii ISSN


The ISSN of Uspehi Molekularnoj Onkologii is 2313805X, 24133787. ISSN stands for International Standard Serial Number.

An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.

Table Setting

Uspehi Molekularnoj Onkologii Rank and SCImago Journal Rank (SJR)


The overall rank of Uspehi Molekularnoj Onkologii is 25726. According to SCImago Journal Rank (SJR), this journal is ranked 0.107. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.

SJR of Uspehi Molekularnoj Onkologii by Year


Year SJR
2023/2024 Coming Soon
2022 0.107
2021 0.115
2020
2019

Ranking of Uspehi Molekularnoj Onkologii by Year


Year Ranking
2023/2024 Coming Soon
2022 25726
2021 23889
2020 34942
2019 32688

Uspehi Molekularnoj Onkologii Publisher


Table Setting

Uspehi Molekularnoj Onkologii is published by ABC-press Publishing House. It's publishing house is located in Russian Federation. Coverage history of this journal is as following: 2019-2022. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.


Call For Papers


Visit the official website of the journal/conference to check the further details about the call for papers.


Abbreviation


The IS0 4 standard abbreviation of Uspehi Molekularnoj Onkologii is Usp. Mol. Onkol.. This abbreviation ('Usp. Mol. Onkol.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.

ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.


How to publish in Uspehi Molekularnoj Onkologii


If your research field is/are related to Biochemistry (medical) (Q4); Cancer Research (Q4); Genetics (clinical) (Q4); Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q4), then please visit the official website of this journal.


Acceptance Rate


The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.

  • The demand or interest of researchers/scientists in publishing in a specific Journal/Conference.
  • Peer review complexity and timeline.
  • The mix of unsolicited and invited submissions.
  • The time it takes from manuscript submission to final publication.
  • And Many More.

It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.

The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.



Frequently Asked Questions (FAQs)


What's the latest impact IF of the Uspehi Molekularnoj Onkologii?

Uspehi Molekularnoj Onkologii latest impact IF is 0.17. It's evaluated in the year 2022. The highest and the lowest impact IF or impact score of this journal are 0.38 (2021) and 0.00 (2019), respectively, in the last 4 years. Moreover, its average IS is 0.22 in the previous 4 years.


What's the SCImago Journal Rank (SJR) of the Uspehi Molekularnoj Onkologii?

The Uspehi Molekularnoj Onkologii has an SJR (SCImago Journal Rank) of 0.107, according to the latest data. It is computed in the year 2023. In the past 4 years, this journal has recorded a range of SJR, with the highest being 0.115 in 2021 and the lowest being in 2020. Furthermore, the average SJR of the Uspehi Molekularnoj Onkologii over the previous 4-year period stands at 0.22.


What's the latest h-index of the Uspehi Molekularnoj Onkologii?

The latest h-index of the Uspehi Molekularnoj Onkologii is 2.


Who's the publisher of the Uspehi Molekularnoj Onkologii?

The Uspehi Molekularnoj Onkologii is published by the ABC-press Publishing House, with its country of publication being the Russian Federation.


What's the current ranking of the Uspehi Molekularnoj Onkologii?

The Uspehi Molekularnoj Onkologii is currently ranked 25726 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 4 years, this journal has experienced varying rankings, reaching its highest position of 23889 in 2021 and its lowest position of 34942 in 2020.


What's the abbreviation or short name for the Uspehi Molekularnoj Onkologii?

The standard ISO4 abbreviation for the Uspehi Molekularnoj Onkologii is Usp. Mol. Onkol..


Is the "Uspehi Molekularnoj Onkologii" classified as a Journal, Conference and Proceedings, Trade Journal or Book Series?

Uspehi Molekularnoj Onkologii is classified as a journal that the ABC-press Publishing House publishes.


What's the scope or major areas of the Uspehi Molekularnoj Onkologii?

The Uspehi Molekularnoj Onkologii encompasses the following areas:

  • Biochemistry (medical)
  • Cancer Research
  • Genetics (clinical)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

For a more comprehensive understanding of its scope, check the official website of this journal.


What's the ISSN of the Uspehi Molekularnoj Onkologii?

The Uspehi Molekularnoj Onkologii is assigned the following International Standard Serial Numbers (ISSN): 2313805X, 24133787.


What's the best quartile of the Uspehi Molekularnoj Onkologii?

The best quartile for the Uspehi Molekularnoj Onkologii is Q4 (2022).


What's the coverage history of the Uspehi Molekularnoj Onkologii?

The Uspehi Molekularnoj Onkologii coverage history can be summarized as follows: 2019-2022.


Credits and Sources


  • Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/
  • Journal Impact Factor, https://clarivate.com/



Impact Score, h-Index, and Other Important Details of These Journals, Conferences, and Books


Journal/Conference/Workshop/Book Title Type Ranking Publisher h-index Impact Score
World Englishes journal 4960 Wiley-Blackwell 60 1.97
Canadian Journal of Education journal 17961 Canadian Society for the Study of Education (CSSE) 41 0.39
Modern Language Journal journal 918 Wiley-Blackwell 103 3.89
Sex Education journal 5168 Routledge 41 2.82
Transnational Corporations journal 6120 UNCTAD United Nations Conference on Trade and Development 27 1.92
Palaeontographica Abteilung B: Palaeophytologie book series 15138 E. Schweizerbart'sche Verlagsbuchhandlung 16 2.20
European Surgery - Acta Chirurgica Austriaca journal 16873 Springer Medizin 23 0.58
Population Review journal 17841 Sociological Demography Press 13 0.73
Journal des Professionnels de l'Enfance journal 27577 TPMA 2 0.00
Archiv fur Geflugelkunde journal 28770 Verlag Eugen Ulmer 30 0.00

Check complete list




Year wise Impact Score (IS) of Uspehi Molekularnoj Onkologii

Impact Score Table

Year Impact Score (IS)
2023/2024 Coming Soon
2022 0.17
2021 0.38
2020 0.33
2019 0.00



Top Journals/Conferences in Biochemistry (medical)

Chem
Elsevier Inc. | United States

Journal of Biomedical Science
BioMed Central Ltd. | United Kingdom

Biomarker Research
BioMed Central Ltd. | United Kingdom

Translational Research
Mosby Inc. | United States

Critical Reviews in Clinical Laboratory Sciences
Informa Healthcare | United Kingdom

Journal of Clinical Endocrinology and Metabolism
Endocrine Society | United States

Clinical Chemistry
American Association for Clinical Chemistry Inc. | United States

Apoptosis : an international journal on programmed cell death
Springer Netherlands | Netherlands

Chemical Record
John Wiley & Sons Inc. | United States

Clinical Chemistry and Laboratory Medicine
Walter de Gruyter GmbH | Germany

See All

Top Journals/Conferences in Cancer Research

Nature Reviews Cancer
Nature Publishing Group | United Kingdom

Cancer Cell
Cell Press | United States

Cell Host and Microbe
Cell Press | United States

Journal of Clinical Oncology
Lippincott Williams and Wilkins Ltd. | United States

Nature Cancer
| United States

Molecular Cancer
BioMed Central Ltd. | United Kingdom

JAMA Oncology
American Medical Association | United States

Signal Transduction and Targeted Therapy
Springer Nature | United Kingdom

Journal of Hematology and Oncology
BioMed Central Ltd. | United Kingdom

Journal of the National Cancer Institute
Oxford University Press | United Kingdom

See All

Top Journals/Conferences in Genetics (clinical)

Nature Reviews Genetics
Nature Publishing Group | United Kingdom

Annual Review of Genomics and Human Genetics
Annual Reviews Inc. | United States

American Journal of Human Genetics
Cell Press | United States

Genome Research
Cold Spring Harbor Laboratory Press | United States

Genome Medicine
BioMed Central Ltd. | United Kingdom

Circulation. Genomic and precision medicine
Lippincott Williams and Wilkins Ltd. | United States

Genetics in Medicine
Elsevier BV | Netherlands

PLoS Genetics
Public Library of Science | United States

npj Genomic Medicine
Nature Publishing Group | United Kingdom

Clinical Epigenetics
BioMed Central Ltd. | United Kingdom

See All

Top Journals/Conferences in Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Acta Pharmaceutica Sinica B
Elsevier BV | Netherlands

Theranostics
Ivyspring International Publisher | Australia

PLoS Neglected Tropical Diseases
Public Library of Science | United States

Current Protocols
John Wiley & Sons Inc. | United States

Life Sciences
Elsevier Inc. | United States

Clinical and Translational Science
Wiley-Blackwell Publishing Ltd | United Kingdom

Drug Metabolism Reviews
Informa Healthcare | United States

Nanotheranostics
Ivyspring International Publishers | Australia

Expert Review of Clinical Pharmacology
Taylor and Francis Ltd. | United Kingdom

F1000Research
| United Kingdom

See All